Bayer’s FINE-REAL Study: Real-World Insights into Finerenone Use

Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.

Study Overview: Bayer AG is conducting a study titled ‘FINE-REAL: A Non-interventional Study Providing Insights Into the Use of Finerenone in a Routine Clinical Setting.’ The study aims to gather real-world data on the use of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). This research is significant as it seeks to understand treatment patterns and outcomes in a routine medical care setting, providing valuable insights into the drug’s effectiveness and safety.

Intervention/Treatment: The study focuses on the drug Kerendia (Finerenone, BAY94-8862), which is designed to block mineralocorticoid receptors to reduce kidney and heart damage. It is prescribed to patients with CKD and T2D to prevent the progression of kidney disease.

Study Design: This observational study follows a cohort model with a prospective time perspective. It involves collecting data from medical records and interviews with participants over a 12-month period to assess treatment patterns and adverse events associated with finerenone.

Study Timeline: The study began on June 13, 2022, with an estimated completion date in September 2027. The most recent update was submitted on July 14, 2025, indicating ongoing recruitment and data collection.

Market Implications: This study could influence Bayer’s stock performance by providing evidence of finerenone’s real-world effectiveness and safety, potentially boosting investor confidence. As finerenone competes in the CKD and T2D treatment market, positive results could enhance its competitive position, impacting the broader industry landscape.

The study is ongoing, with further details available on the ClinicalTrials portal.